SCHEMBL734628

SCHEMBL734628

O=C(S)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
TDP1 Q9NUW8 2/20 0.61
MAPK1 P28482 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SLC6A2 P23975 1/20 0.61
SLC6A3 Q01959 1/20 0.61
KMT2A Q03164 1/20 0.61
LMNA P02545 3/20 0.55
HCAR2 Q8TDS4 1/20 0.55
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.50
CTRB1 P17538 2/20 0.49
TSHR P16473 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11844617 0.98 ALDH1A1 (0.61) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
Hydrochloric Acid SCHEMBL11753013 0.98 ALDH1A1 (0.61) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL3075679 0.84 ALDH1A1 (0.55) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL78553 0.81 ALDH1A1 (0.68) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL27144 0.81 ALDH1A1 (0.68) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL37382 0.81 ALDH1A1 (0.68) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL30001820 0.81 ALDH1A1 (0.68) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL12144939 0.80 KMT2A (0.44) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL3068668 0.79 LMNA (0.57) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2
SCHEMBL12675676 0.79 ALDH1A1 (0.63) ALDH1A1TDP1MAPK1L3MBTL1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034100-B2 Heterogeneous reaction method for preparing functionalized polyanilines NATIONAL TSING HUA UNIVERSITY (TW) 2006-04-25 US claimed
US-20020081275-A1 Heterogeneous reaction method for preparing functionalized polyanilines NATIONAL TSING HUA UNIVERSITY (TW) 2002-06-27 US claimed
US-4386096-A ANGIOTENSIN-CONVERTING ENZYME INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 1983-05-31 US claimed
US-20240376133-A9 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-11-14 US disclosed
EP-4396354-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-10 EP disclosed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
WO-2024130217-A1 STAPLED PEPTIDES AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
WO-2024130218-A1 STAPLED PEPTIDES AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
CN-118159910-A Additive-containing silicon-containing resist underlayer film forming composition 日产化学株式会社 2024-06-07 CN disclosed
EP-4355350-A1 STAPLED PEPTIDES AND METHODS THEREOF Fog Pharmaceuticals, Inc. (US) 2024-04-24 EP disclosed
US-20230416283-A1 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-12-28 US disclosed
US-5504108-A ANTIAGGLOMERANTS, ANTIARTHRITIC AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1996-04-02 US disclosed
WO-1995032194-A1 SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1995-11-30 WO disclosed
WO-1995023139-A1 OPTICALLY PURE 4-ARYL-2-HYDROXYTETRONIC ACIDS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1995-08-31 WO disclosed
US-5399721-A Anticoagulant; prepared from aldehyde THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1995-03-21 US disclosed
EP-0640594-A1 Hydantoin derivative as metalloprotease inhibitor FUJIREBIO INC. (JP) 1995-03-01 EP disclosed
CN-1073176-A Amino alkyl pyrrolidyl carbapenem derivative UNIVERSAL PHARMACEUTICAL CO LT (JP) 1993-06-16 CN disclosed
EP-0038117-A1 Methods for preparing anti-hypertensive agents UNIVERSITY OF MIAMI (US) 1981-10-21 EP disclosed
EP-0004773-A2 17-Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes, their pharmaceutical use and processes for their preparation SYNTEX (U.S.A.) INC. (US) 1979-10-17 EP disclosed
EP-0004741-A2 Thio etianic acid derivatives, their preparation and pharmaceutical use SYNTEX (U.S.A.) INC. (US) 1979-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376133-A9 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS PGD, CDCA2, MCM2 ALDH1A1 625/4885TDP1 87/4885MAPK1 1611/4885
US-20020081275-A1 Heterogeneous reaction method for preparing functionalized polyanilines PARG, TET2, ROS1 ALDH1A1 2186/4885TDP1 2074/4885MAPK1 1868/4885
US-20230416283-A1 CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS PGD, CDCA2, MCM2 ALDH1A1 625/4885TDP1 87/4885MAPK1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.